Explainable AI for wearable seizure logging: Impact of data quality, patient age, and antiseizure medication on performance.
Antiseizure medication
Automatic seizure logging
Autonomous nervous system
Deep learning
Epilepsy
Explainable artificial intelligence
Tonic-clonic seizure
Wearables
Journal
Seizure
ISSN: 1532-2688
Titre abrégé: Seizure
Pays: England
ID NLM: 9306979
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
27
02
2023
revised:
16
05
2023
accepted:
04
06
2023
medline:
4
8
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
ppublish
Résumé
Objective seizure count estimates are crucial for ambulatory epilepsy management. Wearables have shown promise for the detection of tonic-clonic seizures but may suffer from false alarms and undetected seizures. Seizure signatures recorded by wearables often occur over prolonged periods, including increased levels of electrodermal activity and heart rate long after seizure EEG onset, however, previous detection methods only partially exploited these signatures. Understanding the utility of these prolonged signatures for seizure count estimation and what factors generally determine seizure logging performance, including the role of data quality vs. algorithm performance, is thus crucial for improving wearables-based epilepsy monitoring and determining which patients benefit most from this technology. In this retrospective study we examined 76 pediatric epilepsy patients during multiday video-EEG monitoring equipped with a wearable (Empatica E4; records of electrodermal activity, EDA, accelerometry, ACC, heart rate, HR; 1983 h total recording time; 45 tonic-clonic seizures). To log seizures on prolonged data trends, we applied deep learning on continuous overlapping 1-hour segments of multimodal data in a leave-one-subject-out approach. We systematically examined factors influencing logging performance, including patient age, antiseizure medication (ASM) load, seizure type and duration, and data artifacts. To gain insights into algorithm function and feature importance we applied Uniform Manifold Approximation and Projection (UMAP, to represent the separability of learned features) and SHapley Additive exPlanations (SHAP, to represent the most informative data signatures). Performance for tonic-clonic seizure logging increased systematically with patient age (AUC 0.61 for patients 〈 11 years, AUC 0.77 for patients between 11-15 years, AUC 0.85 for patients 〉 15 years). Across all ages, AUC was 0.75 corresponding to a sensitivity of 0.52 and a false alarm rate of 0.28/24 h. Seizures under high ASM load or with shorter duration were detected worse (P=.025, P=.033, respectively). UMAP visualized discriminatory power at the individual patient level, SHAP analyses identified clonic motor activity and peri/postictal increases in HR and EDA as most informative. In contrast, in missed seizures, these features were absent indicating that recording quality but not the algorithm caused the low sensitivity in these patients. Our results demonstrate the utility of prolonged, postictal data segments for seizure logging, contribute to algorithm explainability and point to influencing factors, including high ASM dose and short seizure duration. Collectively, these results may help to identify patients who particularly benefit from such technology.
Identifiants
pubmed: 37336056
pii: S1059-1311(23)00155-3
doi: 10.1016/j.seizure.2023.06.002
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-108Informations de copyright
Copyright © 2023 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest CM is part of pending and approved patents related to seizure detection, seizure prediction, and epilepsy diagnosis. TL has received funding from Empatica in the past, has received device donations from Empatica in the past, and is part of pending and approved patents related to seizure detection, seizure prediction, and epilepsy diagnosis. SV is part of a patent covering technology for seizure forecasting. The rest of the authors declare no conflicting interests.